Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avicidin cancer therapy data

NERX reported on nine of 11 patients enrolled in the dosimetry monitoring portion of its Phase I trial, announcing an eight-fold improvement in the tumor-to-blood ratio with pre-targeting, compared to conventional use

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE